cefazolin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 530 25953-19-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefazolin
  • cefazolin sodium
  • cefamezin
  • cefaprim
  • cefazoline
  • cephamezine
  • cephazolin
  • cephazoline
  • cefazolin sodium salt
A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.
  • Molecular weight: 454.50
  • Formula: C14H14N8O4S3
  • CLOGP: -0.64
  • LIPINSKI: 1
  • HAC: 12
  • HDO: 2
  • TPSA: 156.09
  • ALOGS: -2.97
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 33 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 80 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 146.75 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.89 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.18 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 4, 1973 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 604.84 13.98 226 15660 23407 63449729
Anaphylactic reaction 279.14 13.98 185 15701 65915 63407221
Hypotension 196.57 13.98 288 15598 272316 63200820
Acute generalised exanthematous pustulosis 178.45 13.98 76 15810 11023 63462113
Arthrodesis 155.65 13.98 48 15838 2753 63470383
Postoperative wound infection 115.93 13.98 56 15830 10869 63462267
Fatigue 95.60 13.98 52 15834 887976 62585160
Bronchospasm 91.84 13.98 56 15830 17224 63455912
Erythema 83.37 13.98 154 15732 175597 63297539
Type I hypersensitivity 81.99 13.98 30 15856 2912 63470224
Exposure during pregnancy 73.37 13.98 136 15750 155411 63317725
Urticaria 70.85 13.98 139 15747 165663 63307473
Cardiac arrest 66.72 13.98 98 15788 92447 63380689
Tachycardia 64.30 13.98 110 15776 118046 63355090
Vitamin K deficiency 63.78 13.98 16 15870 424 63472712
Drug hypersensitivity 63.44 13.98 196 15690 310491 63162645
Shoulder arthroplasty 59.70 13.98 26 15860 3976 63469160
Premature delivery 59.70 13.98 54 15832 30227 63442909
Premature baby 59.62 13.98 46 15840 20689 63452447
Amniotic cavity infection 59.16 13.98 19 15867 1244 63471892
Limb operation 56.28 13.98 25 15861 4006 63469130
Drug-induced liver injury 55.48 13.98 59 15827 40163 63432973
Hypoprothrombinaemia 54.48 13.98 13 15873 278 63472858
Blood pressure decreased 52.96 13.98 73 15813 64949 63408187
Renal failure 51.88 13.98 100 15786 117552 63355584
Kounis syndrome 49.54 13.98 18 15868 1712 63471424
Anaesthetic complication 47.35 13.98 18 15868 1942 63471194
Alopecia 47.29 13.98 13 15873 337523 63135613
Bradycardia 44.95 13.98 72 15814 73155 63399981
Drug intolerance 44.93 13.98 11 15875 308650 63164486
Maternal exposure during delivery 44.42 13.98 16 15870 1484 63471652
Renal injury 43.62 13.98 28 15858 9411 63463725
Rash 41.74 13.98 261 15625 560610 62912526
Coagulopathy 41.20 13.98 37 15849 20507 63452629
Recurrence of neuromuscular blockade 40.72 13.98 9 15877 135 63473001
Toxic epidermal necrolysis 40.06 13.98 40 15846 25294 63447842
Acute hepatic failure 38.73 13.98 34 15852 18293 63454843
Vascular purpura 37.25 13.98 14 15872 1464 63471672
Fear 36.88 13.98 31 15855 15735 63457401
Multiple organ dysfunction syndrome 36.48 13.98 57 15829 56695 63416441
Systemic lupus erythematosus 35.61 13.98 5 15881 208913 63264223
Anhedonia 35.21 13.98 26 15860 10948 63462188
Product dose omission issue 34.78 13.98 8 15878 234305 63238831
Headache 34.04 13.98 67 15819 633174 62839962
Generalised tonic-clonic seizure 33.86 13.98 39 15847 28977 63444159
Pseudomembranous colitis 33.15 13.98 16 15870 3096 63470040
Weight increased 33.02 13.98 12 15874 260780 63212356
Purpura senile 32.77 13.98 10 15876 553 63472583
Post procedural complication 32.77 13.98 30 15856 17044 63456092
Tarsal tunnel syndrome 32.58 13.98 10 15876 564 63472572
Peripheral swelling 32.41 13.98 13 15873 265929 63207207
Unevaluable event 32.18 13.98 51 15835 51335 63421801
Isoimmune haemolytic disease 31.95 13.98 6 15880 37 63473099
Disseminated intravascular coagulation 31.83 13.98 31 15855 19020 63454116
Hepatic function abnormal 30.68 13.98 42 15844 37100 63436036
Face oedema 30.29 13.98 31 15855 20181 63452955
Cholestasis 30.12 13.98 37 15849 29397 63443739
Wound 30.06 13.98 3 15883 163260 63309876
Clostridium test positive 29.76 13.98 15 15871 3186 63469950
Swelling 29.63 13.98 16 15870 275362 63197774
Sinusitis 29.43 13.98 10 15876 226643 63246493
Thrombotic microangiopathy 29.42 13.98 23 15863 10538 63462598
Oxygen saturation decreased 29.34 13.98 67 15819 88518 63384618
Angioedema 29.20 13.98 47 15839 47918 63425218
Joint swelling 28.61 13.98 24 15862 327642 63145494
Therapeutic product effect decreased 27.87 13.98 7 15879 193180 63279956
Acute kidney injury 27.85 13.98 135 15751 263280 63209856
Foetal anaemia 26.79 13.98 6 15880 96 63473040
Pain 26.43 13.98 96 15790 740532 62732604
Hepatitis cholestatic 25.98 13.98 18 15868 6860 63466276
Pain in extremity 25.74 13.98 27 15859 331459 63141677
Toxic skin eruption 25.43 13.98 23 15863 12862 63460274
Death 25.33 13.98 34 15852 374347 63098789
Hyperthermia malignant 25.09 13.98 9 15877 825 63472311
Post procedural haematoma 24.70 13.98 10 15876 1275 63471861
Malaise 24.09 13.98 42 15844 415912 63057224
Infusion related reaction 23.97 13.98 16 15870 245505 63227631
Haemolytic anaemia 23.87 13.98 20 15866 10105 63463031
Treatment failure 23.80 13.98 10 15876 199033 63274103
Tonic clonic movements 23.63 13.98 10 15876 1425 63471711
Altered state of consciousness 23.09 13.98 30 15856 25200 63447936
Pleural effusion 22.98 13.98 63 15823 93147 63379989
Implant site haematoma 22.50 13.98 5 15881 77 63473059
Eosinophilia 22.31 13.98 28 15858 22728 63450408
Heparin-induced thrombocytopenia 22.19 13.98 14 15872 4568 63468568
Resorption bone increased 21.39 13.98 9 15877 1265 63471871
Low birth weight baby 20.89 13.98 16 15870 7113 63466023
Injury 20.59 13.98 52 15834 73195 63399941
Nasopharyngitis 20.54 13.98 20 15866 254237 63218899
Drug reaction with eosinophilia and systemic symptoms 20.38 13.98 33 15853 33803 63439333
Vestibular disorder 20.38 13.98 9 15877 1422 63471714
Aspartate aminotransferase increased 20.28 13.98 59 15827 90218 63382918
Pulseless electrical activity 20.13 13.98 16 15870 7505 63465631
Shock 20.08 13.98 27 15859 23436 63449700
Staphylococcal bacteraemia 19.79 13.98 14 15872 5516 63467620
Asthenia 19.36 13.98 42 15844 383562 63089574
Mixed liver injury 19.33 13.98 13 15873 4722 63468414
Post procedural haemorrhage 19.33 13.98 16 15870 7948 63465188
Eyelid oedema 19.31 13.98 18 15868 10461 63462675
Hypoventilation 19.28 13.98 13 15873 4741 63468395
Clostridium difficile infection 19.14 13.98 30 15856 29892 63443244
Pyomyositis 19.04 13.98 6 15880 369 63472767
Lip oedema 19.02 13.98 12 15874 3912 63469224
Arthralgia 18.89 13.98 76 15810 569634 62903502
Alanine aminotransferase increased 18.85 13.98 63 15823 103707 63369429
Hypokalaemia 18.84 13.98 63 15823 103741 63369395
Laryngeal dyspnoea 18.59 13.98 5 15881 175 63472961
Hepatic cytolysis 18.46 13.98 21 15865 15386 63457750
Spinal cord haematoma 18.46 13.98 5 15881 180 63472956
Eosinophilic pneumonia acute 18.29 13.98 6 15880 420 63472716
Shock haemorrhagic 18.24 13.98 17 15869 9878 63463258
Manipulation 18.23 13.98 4 15882 58 63473078
Cerebral infarction 18.21 13.98 26 15860 23867 63449269
Injection site pain 18.15 13.98 5 15881 129795 63343341
Musculoskeletal stiffness 18.06 13.98 12 15874 184606 63288530
Mycobacterial peritonitis 18.04 13.98 4 15882 61 63473075
Oligohydramnios 18.03 13.98 14 15872 6352 63466784
Allergy test negative 17.97 13.98 5 15881 199 63472937
Respiratory failure 17.76 13.98 61 15825 101797 63371339
Glomerular filtration rate abnormal 17.76 13.98 7 15879 832 63472304
Procedural complication 17.70 13.98 13 15873 5426 63467710
Abdominal wound dehiscence 17.49 13.98 5 15881 220 63472916
Haemodynamic instability 17.34 13.98 16 15870 9174 63463962
Emotional distress 17.28 13.98 30 15856 32519 63440617
Device related infection 17.16 13.98 25 15861 23367 63449769
Deep vein thrombosis 17.15 13.98 53 15833 83747 63389389
Linear IgA disease 17.11 13.98 8 15878 1443 63471693
Circulatory collapse 16.91 13.98 24 15862 21914 63451222
Weight decreased 16.88 13.98 27 15859 276771 63196365
Gastrointestinal disorder 16.66 13.98 6 15880 131233 63341903
Clostridium difficile colitis 16.59 13.98 23 15863 20546 63452590
Jaundice acholuric 16.44 13.98 4 15882 93 63473043
Anaemia 16.11 13.98 127 15759 293303 63179833
Intentional product use issue 15.98 13.98 6 15880 127886 63345250
Decorticate posture 15.96 13.98 5 15881 302 63472834
Dizziness 15.77 13.98 55 15831 429870 63043266
Renal impairment 15.48 13.98 53 15833 88302 63384834
Therapeutic product effect incomplete 15.40 13.98 6 15880 125050 63348086
Irregular breathing 15.34 13.98 5 15881 343 63472793
Arthrofibrosis 15.30 13.98 3 15883 24 63473112
Apnoea 15.20 13.98 14 15872 8008 63465128
Toxicity to various agents 15.19 13.98 24 15862 247226 63225910
Insomnia 15.10 13.98 19 15867 215233 63257903
Discomfort 14.91 13.98 12 15874 167362 63305774
Peritoneal cloudy effluent 14.88 13.98 4 15882 140 63472996
Brain oedema 14.77 13.98 18 15868 14177 63458959
Renal vein thrombosis 14.63 13.98 5 15881 397 63472739
Mobility decreased 14.62 13.98 6 15880 121153 63351983
Multiple lentigines syndrome 14.51 13.98 4 15882 154 63472982
Hypopnoea 14.47 13.98 10 15876 3796 63469340
Septic shock 14.44 13.98 43 15843 66586 63406550
Atelectasis 14.39 13.98 22 15864 21461 63451675
Hypoxia 14.32 13.98 40 15846 59752 63413384
Delivery 14.30 13.98 7 15879 1396 63471740
Keratitis fungal 14.29 13.98 4 15882 163 63472973
Serratia test positive 14.27 13.98 3 15883 35 63473101
Bradycardia foetal 14.24 13.98 5 15881 431 63472705
Muscle spasms 14.15 13.98 11 15875 156139 63316997
Endotracheal intubation complication 14.11 13.98 5 15881 442 63472694

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 391.99 14.89 169 13831 15772 34927159
Anaphylactic reaction 273.97 14.89 167 13833 32134 34910797
Hypoprothrombinaemia 160.79 14.89 36 13964 346 34942585
Kounis syndrome 97.35 14.89 37 13963 2481 34940450
Fear 96.01 14.89 57 13943 10419 34932512
Drug reaction with eosinophilia and systemic symptoms 82.87 14.89 83 13917 32929 34910002
Thymus hypoplasia 80.65 14.89 21 13979 397 34942534
Lymphoid tissue hypoplasia 80.65 14.89 21 13979 397 34942534
Hypotension 79.42 14.89 231 13769 221418 34721513
Renal injury 75.14 14.89 50 13950 11145 34931786
Anhedonia 74.05 14.89 43 13957 7542 34935389
Injury 73.20 14.89 63 13937 20624 34922307
Acute generalised exanthematous pustulosis 73.09 14.89 41 13959 6735 34936196
Disseminated aspergillosis 67.70 14.89 21 13979 759 34942172
Emotional distress 61.95 14.89 50 13950 14976 34927955
Clostridium difficile colitis 59.94 14.89 50 13950 15680 34927251
Fatigue 59.10 14.89 38 13962 370615 34572316
Bronchospasm 55.82 14.89 41 13959 10690 34932241
Vitamin K deficiency 54.20 14.89 14 13986 256 34942675
Allergy test negative 53.25 14.89 12 13988 119 34942812
Urticaria 53.08 14.89 92 13908 62285 34880646
Hypovitaminosis 51.43 14.89 16 13984 584 34942347
Erythema 46.62 14.89 107 13893 88673 34854258
Clostridium test positive 43.77 14.89 23 13977 3319 34939612
Unevaluable event 43.14 14.89 59 13941 32531 34910400
Brain herniation 42.54 14.89 24 13976 3984 34938947
Post procedural hypotension 42.36 14.89 9 13991 66 34942865
Death 41.14 14.89 60 13940 397989 34544942
Post procedural complication 40.92 14.89 35 13965 11353 34931578
Vitamin K decreased 39.33 14.89 8 13992 46 34942885
Dizziness 38.16 14.89 20 13980 218501 34724430
Tubulointerstitial nephritis 37.22 14.89 44 13956 20980 34921951
Cytomegalovirus viraemia 35.54 14.89 27 13973 7403 34935528
Rash maculo-papular 35.39 14.89 50 13950 28401 34914530
Blood pressure decreased 35.02 14.89 69 13931 51446 34891485
Rash 34.45 14.89 178 13822 222574 34720357
Coagulopathy 34.35 14.89 41 13959 19748 34923183
Shock 33.86 14.89 45 13955 24134 34918797
Weight decreased 32.48 14.89 15 13985 176286 34766645
Hyperthermia malignant 31.44 14.89 16 13984 2161 34940770
Adrenal suppression 30.50 14.89 11 13989 636 34942295
Post procedural haematoma 30.46 14.89 14 13986 1512 34941419
Gastritis fungal 29.77 14.89 7 13993 85 34942846
Metabolic acidosis 29.07 14.89 58 13942 43622 34899309
Jaundice cholestatic 28.80 14.89 20 13980 4774 34938157
Renal failure 28.07 14.89 115 13885 130442 34812489
Pathogen resistance 27.83 14.89 26 13974 9456 34933475
Coagulation factor X level decreased 27.45 14.89 5 13995 14 34942917
Linear IgA disease 26.58 14.89 13 13987 1613 34941318
Multiple organ dysfunction syndrome 26.51 14.89 79 13921 76487 34866444
Ventricular tachycardia 26.33 14.89 42 13958 26537 34916394
Pericarditis fungal 25.83 14.89 7 13993 155 34942776
Eosinophilia 25.38 14.89 41 13959 26181 34916750
Angioedema 25.32 14.89 50 13950 37324 34905607
Renal impairment 25.04 14.89 89 13911 94424 34848507
Serotonin syndrome 24.74 14.89 35 13965 19898 34923033
Fungal infection 24.40 14.89 31 13969 15904 34927027
Pseudomonal sepsis 24.17 14.89 16 13984 3531 34939400
Device related infection 24.01 14.89 32 13968 17205 34925726
Hepatic function abnormal 23.84 14.89 54 13946 44309 34898622
Rash morbilliform 23.68 14.89 15 13985 3072 34939859
Stress 23.52 14.89 43 13957 30304 34912627
Meningitis fungal 23.27 14.89 6 13994 109 34942822
Embolic stroke 23.12 14.89 17 13983 4437 34938494
Strongyloidiasis 22.89 14.89 14 13986 2697 34940234
Type I hypersensitivity 22.77 14.89 11 13989 1328 34941603
Toxic epidermal necrolysis 22.54 14.89 35 13965 21611 34921320
Burkholderia test positive 22.36 14.89 10 13990 1013 34941918
Product dose omission issue 22.32 14.89 10 13990 119701 34823230
Malaise 22.24 14.89 25 13975 185800 34757131
Arterial angioplasty 22.15 14.89 5 13995 50 34942881
Drug eruption 21.88 14.89 33 13967 19865 34923066
Toxicity to various agents 21.82 14.89 29 13971 200333 34742598
Diarrhoea 21.54 14.89 82 13918 389830 34553101
Myoclonus 21.53 14.89 28 13972 14697 34928234
Anaesthetic complication 21.50 14.89 10 13990 1110 34941821
Conjunctival ulcer 21.47 14.89 5 13995 58 34942873
Intrapericardial thrombosis 21.47 14.89 5 13995 58 34942873
Drug hypersensitivity 21.47 14.89 76 13924 80453 34862478
Spontaneous haematoma 21.22 14.89 8 13992 524 34942407
Headache 20.89 14.89 30 13970 200605 34742326
Cardiac arrest 20.88 14.89 85 13915 96074 34846857
Post embolisation syndrome 20.74 14.89 5 13995 68 34942863
Catheter site haemorrhage 20.10 14.89 12 13988 2212 34940719
Factor V inhibition 20.07 14.89 6 13994 191 34942740
Procedural hypotension 19.98 14.89 9 13991 927 34942004
Pyrexia 19.38 14.89 211 13789 332802 34610129
Lymphopenia 19.27 14.89 28 13972 16307 34926624
Tachycardia 19.26 14.89 76 13924 84696 34858235
Post procedural haemorrhage 19.25 14.89 20 13980 8269 34934662
Kidney transplant rejection 19.07 14.89 19 13981 7478 34935453
Tryptase increased 18.98 14.89 6 13994 231 34942700
Drug-induced liver injury 18.84 14.89 38 13962 28794 34914137
Herpes simplex hepatitis 18.80 14.89 5 13995 103 34942828
Cellulitis 18.66 14.89 55 13945 52896 34890035
Viral uveitis 18.52 14.89 4 13996 32 34942899
Disseminated intravascular coagulation 18.30 14.89 32 13968 21784 34921147
Cardiac valve vegetation 18.20 14.89 7 13993 484 34942447
Asthenia 18.20 14.89 45 13955 245206 34697725
Coagulation factor VII level decreased 18.07 14.89 5 13995 120 34942811
Dysbiosis 17.76 14.89 7 13993 517 34942414
Systemic mastocytosis 17.17 14.89 5 13995 145 34942786
Pruritus 16.97 14.89 106 13894 141875 34801056
Haemodynamic instability 16.97 14.89 20 13980 9503 34933428
Bacterial infection 16.95 14.89 27 13973 17036 34925895
Eyelid oedema 16.90 14.89 15 13985 5109 34937822
Blood creatine phosphokinase MB increased 16.59 14.89 10 13990 1876 34941055
Appendicitis perforated 16.48 14.89 10 13990 1898 34941033
Drug chemical incompatibility 16.32 14.89 3 13997 9 34942922
Arteritis 16.31 14.89 6 13994 367 34942564
Nodal rhythm 16.29 14.89 9 13991 1434 34941497
Torsade de pointes 16.03 14.89 17 13983 7192 34935739
Toxic shock syndrome 15.78 14.89 6 13994 402 34942529
Procedural pain 15.71 14.89 14 13986 4792 34938139
Shock haemorrhagic 15.69 14.89 21 13979 11333 34931598
Arthrofibrosis 15.60 14.89 4 13996 71 34942860
Staphylococcal bacteraemia 15.47 14.89 18 13982 8434 34934497
Prothrombin level decreased 15.45 14.89 8 13992 1120 34941811
Haemolytic anaemia 15.43 14.89 20 13980 10459 34932472
Pseudomembranous colitis 15.27 14.89 11 13989 2780 34940151
Laryngeal oedema 15.15 14.89 12 13988 3496 34939435
Reperfusion injury 15.05 14.89 4 13996 82 34942849
Acinetobacter infection 14.94 14.89 8 13992 1199 34941732
Delayed recovery from anaesthesia 14.90 14.89 7 13993 794 34942137

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 945.96 13.04 384 27324 35612 79681068
Anaphylactic reaction 499.69 13.04 329 27379 83414 79633266
Hypotension 246.10 13.04 499 27209 439818 79276862
Acute generalised exanthematous pustulosis 236.85 13.04 117 27591 17137 79699543
Hypoprothrombinaemia 208.42 13.04 49 27659 693 79715987
Kounis syndrome 148.71 13.04 56 27652 4226 79712454
Bronchospasm 136.78 13.04 93 27615 24766 79691914
Fatigue 124.25 13.04 86 27622 929641 78787039
Urticaria 118.96 13.04 223 27485 184978 79531702
Fear 117.99 13.04 81 27627 21905 79694775
Erythema 114.82 13.04 245 27463 223045 79493635
Vitamin K deficiency 108.78 13.04 29 27679 699 79715981
Arthrodesis 107.88 13.04 38 27670 2369 79714311
Renal injury 104.40 13.04 68 27640 16859 79699821
Anhedonia 99.68 13.04 63 27645 14835 79701845
Drug reaction with eosinophilia and systemic symptoms 94.36 13.04 114 27594 64130 79652550
Lymphoid tissue hypoplasia 92.83 13.04 27 27681 903 79715777
Type I hypersensitivity 92.15 13.04 40 27668 4358 79712322
Thymus hypoplasia 91.62 13.04 27 27681 946 79715734
Disseminated aspergillosis 87.92 13.04 27 27681 1091 79715589
Drug-induced liver injury 85.39 13.04 110 27598 66007 79650673
Unevaluable event 82.23 13.04 99 27609 55486 79661194
Clostridium difficile colitis 80.70 13.04 76 27632 32207 79684473
Blood pressure decreased 79.62 13.04 132 27576 99334 79617346
Rash 77.03 13.04 400 27308 577958 79138722
Renal failure 76.40 13.04 196 27512 200772 79515908
Coagulopathy 73.70 13.04 76 27632 35930 79680750
Clostridium test positive 71.81 13.04 38 27670 6416 79710264
Cardiac arrest 69.75 13.04 172 27536 171924 79544756
Allergy test negative 67.90 13.04 17 27691 317 79716363
Tachycardia 67.17 13.04 173 27535 177595 79539085
Post procedural complication 65.19 13.04 59 27649 23770 79692910
Emotional distress 63.76 13.04 74 27634 39895 79676785
Injury 63.57 13.04 104 27604 77392 79639288
Headache 58.97 13.04 85 27623 653687 79062993
Anaesthetic complication 56.64 13.04 25 27683 2834 79713846
Toxic epidermal necrolysis 54.17 13.04 72 27636 44509 79672171
Joint swelling 51.50 13.04 18 27690 288628 79428052
Drug hypersensitivity 50.75 13.04 222 27486 298694 79417986
Dizziness 49.89 13.04 66 27642 526375 79190305
Multiple organ dysfunction syndrome 49.56 13.04 121 27587 120125 79596555
Vitamin K decreased 49.40 13.04 10 27698 66 79716614
Shock 49.37 13.04 68 27640 43480 79673200
Eosinophilia 48.71 13.04 69 27639 45276 79671404
Hepatic function abnormal 48.07 13.04 89 27619 73018 79643662
Bradycardia 47.19 13.04 128 27580 135429 79581251
Hypovitaminosis 47.11 13.04 17 27691 1137 79715543
Product dose omission issue 46.69 13.04 14 27694 247523 79469157
Weight increased 46.64 13.04 19 27689 277367 79439313
Malaise 45.81 13.04 62 27646 489807 79226873
Cytomegalovirus viraemia 45.80 13.04 37 27671 12784 79703896
Disseminated intravascular coagulation 45.27 13.04 59 27649 35783 79680897
Toxicity to various agents 45.10 13.04 48 27660 421492 79295188
Brain herniation 43.63 13.04 29 27679 7434 79709246
Weight decreased 43.20 13.04 36 27672 355162 79361518
Angioedema 43.17 13.04 87 27621 75948 79640732
Rash maculo-papular 42.96 13.04 73 27635 56005 79660675
Death 42.40 13.04 83 27625 566431 79150249
Linear IgA disease 42.25 13.04 21 27687 3111 79713569
Post procedural hypotension 42.09 13.04 9 27699 80 79716600
Alopecia 42.00 13.04 14 27694 231341 79485339
Pseudomembranous colitis 41.74 13.04 25 27683 5349 79711331
Drug intolerance 41.39 13.04 20 27688 264099 79452581
Post procedural haematoma 40.92 13.04 19 27689 2423 79714257
Tubulointerstitial nephritis 40.80 13.04 58 27650 38177 79678503
Sinusitis 40.80 13.04 9 27699 195492 79521188
Hyperthermia malignant 40.67 13.04 20 27688 2897 79713783
Peripheral swelling 39.90 13.04 22 27686 269595 79447085
Renal impairment 39.80 13.04 133 27575 157650 79559030
Vascular purpura 39.53 13.04 20 27688 3078 79713602
Arthralgia 38.43 13.04 89 27619 571714 79144966
Face oedema 38.18 13.04 48 27660 28088 79688592
Device related infection 36.56 13.04 52 27656 34242 79682438
Diarrhoea 36.38 13.04 170 27538 880319 78836361
Haemolytic anaemia 35.35 13.04 37 27671 17783 79698897
Staphylococcal bacteraemia 34.89 13.04 31 27677 12187 79704493
Maternal exposure during delivery 34.06 13.04 14 27694 1332 79715348
Pseudomonal sepsis 33.72 13.04 23 27685 6151 79710529
Premature delivery 33.39 13.04 41 27667 23426 79693254
Asthenia 33.28 13.04 81 27627 511608 79205072
Ventricular tachycardia 32.66 13.04 55 27653 41880 79674800
Pain in extremity 32.20 13.04 48 27660 364490 79352190
Eyelid oedema 31.88 13.04 31 27677 13656 79703024
Toxic skin eruption 31.80 13.04 39 27669 22254 79694426
Post procedural haemorrhage 31.77 13.04 31 27677 13713 79702967
Nasopharyngitis 31.76 13.04 25 27683 253856 79462824
Procedural hypotension 31.62 13.04 15 27693 2008 79714672
Injection site pain 31.45 13.04 4 27704 129834 79586846
Cholestasis 31.23 13.04 61 27647 52048 79664632
Haemodynamic instability 30.81 13.04 34 27674 17348 79699332
Recurrence of neuromuscular blockade 30.68 13.04 9 27699 310 79716370
Shock haemorrhagic 30.09 13.04 36 27672 20024 79696656
Shoulder arthroplasty 30.08 13.04 17 27691 3265 79713415
Intentional product use issue 29.79 13.04 8 27700 152104 79564576
Pulseless electrical activity 29.17 13.04 30 27678 14130 79702550
Arthrofibrosis 29.02 13.04 7 27701 111 79716569
Heparin-induced thrombocytopenia 28.52 13.04 25 27683 9657 79707023
Strongyloidiasis 27.37 13.04 17 27691 3881 79712799
Infusion related reaction 27.16 13.04 24 27684 230213 79486467
Pathogen resistance 27.07 13.04 29 27679 14313 79702367
Drug eruption 27.02 13.04 52 27656 43883 79672797
Limb operation 26.77 13.04 16 27692 3410 79713270
Systemic lupus erythematosus 26.47 13.04 5 27703 121144 79595536
Septic shock 26.21 13.04 98 27610 122703 79593977
Purpura senile 26.19 13.04 9 27699 521 79716159
Tarsal tunnel syndrome 26.09 13.04 9 27699 527 79716153
Pyrexia 25.88 13.04 354 27354 678355 79038325
Conjunctival ulcer 25.84 13.04 6 27702 80 79716600
Pericarditis fungal 25.79 13.04 7 27701 181 79716499
Acute hepatic failure 25.47 13.04 41 27667 30072 79686608
Gastritis fungal 25.43 13.04 7 27701 191 79716489
Dysbiosis 25.25 13.04 11 27697 1208 79715472
Insomnia 25.00 13.04 29 27679 245141 79471539
Metabolic acidosis 24.87 13.04 74 27634 82455 79634225
Gastrointestinal disorder 24.74 13.04 6 27702 122199 79594481
Hepatic enzyme abnormal 24.69 13.04 21 27687 7789 79708891
Rash morbilliform 24.66 13.04 19 27689 6131 79710549
Tryptase increased 24.35 13.04 9 27699 644 79716036
Tonic clonic movements 24.25 13.04 13 27695 2251 79714429
Laryngeal oedema 23.96 13.04 21 27687 8108 79708572
Respiratory failure 23.86 13.04 125 27583 180786 79535894
Adrenal suppression 23.80 13.04 11 27697 1388 79715292
Contusion 23.70 13.04 11 27697 148765 79567915
Pruritus 23.69 13.04 225 27483 394423 79322257
Off label use 23.56 13.04 202 27506 907013 78809667
Muscle spasms 23.41 13.04 16 27692 174714 79541966
Cellulitis 23.25 13.04 87 27621 108973 79607707
Necrotising oesophagitis 22.92 13.04 10 27698 1103 79715577
Intentional product misuse 22.88 13.04 3 27705 95162 79621518
Mobility decreased 22.86 13.04 7 27701 122168 79594512
Arterial angioplasty 22.85 13.04 5 27703 50 79716630
Musculoskeletal pain 22.84 13.04 4 27704 102350 79614330
Embolic stroke 22.63 13.04 20 27688 7806 79708874
Brain oedema 22.20 13.04 35 27673 25228 79691452
Intrapericardial thrombosis 22.18 13.04 5 27703 58 79716622
Clostridium difficile infection 22.06 13.04 47 27661 42638 79674042
Acinetobacter infection 21.78 13.04 13 27695 2764 79713916
Airway peak pressure increased 21.57 13.04 7 27701 339 79716341
Lower respiratory tract infection 21.46 13.04 9 27699 129211 79587469
Pyomyositis 21.07 13.04 8 27700 617 79716063
Oropharyngeal pain 20.94 13.04 6 27702 109347 79607333
Catheter site haemorrhage 20.94 13.04 16 27692 5101 79711579
Musculoskeletal stiffness 20.93 13.04 18 27690 174990 79541690
Meningitis fungal 20.88 13.04 6 27702 192 79716488
Fall 20.75 13.04 93 27615 487536 79229144
Manipulation 20.75 13.04 5 27703 79 79716601
Therapeutic product effect decreased 20.66 13.04 16 27692 163847 79552833
Thrombotic microangiopathy 20.64 13.04 30 27678 20139 79696541
Post embolisation syndrome 20.46 13.04 5 27703 84 79716596
Skin graft 20.41 13.04 9 27699 1018 79715662
Contraindicated product administered 20.35 13.04 15 27693 157523 79559157
Circulatory collapse 20.07 13.04 42 27666 37626 79679054
Asthma 20.00 13.04 11 27697 135084 79581596
Macular oedema 19.98 13.04 16 27692 5458 79711222
Procedural haemorrhage 19.88 13.04 15 27693 4691 79711989
Myoclonus 19.86 13.04 35 27673 27625 79689055
Kidney transplant rejection 19.84 13.04 21 27687 10225 79706455
Aspartate aminotransferase increased 19.82 13.04 98 27610 138543 79578137
Electrocardiogram ST segment elevation 19.52 13.04 19 27689 8378 79708302
Hepatitis cholestatic 19.38 13.04 24 27684 13828 79702852
Cholestatic liver injury 19.23 13.04 15 27693 4926 79711754
Bacterial infection 19.21 13.04 37 27671 31243 79685437
Coagulation factor X level decreased 19.19 13.04 5 27703 110 79716570
Blood creatine phosphokinase MB increased 19.08 13.04 12 27696 2799 79713881
Delayed recovery from anaesthesia 19.03 13.04 10 27698 1663 79715017
Postoperative wound infection 19.02 13.04 23 27685 12938 79703742
Endotracheal intubation complication 18.95 13.04 8 27700 814 79715866
Generalised tonic-clonic seizure 18.95 13.04 45 27663 43865 79672815
Treatment failure 18.66 13.04 19 27689 170467 79546213
Lymphopenia 18.59 13.04 36 27672 30521 79686159
Disease progression 18.58 13.04 22 27686 184340 79532340
Hypoxia 18.49 13.04 78 27630 103165 79613515
Diabetes insipidus 18.46 13.04 15 27693 5222 79711458
Herpes simplex hepatitis 18.46 13.04 7 27701 538 79716142
Migraine 18.30 13.04 4 27704 87489 79629191
Memory impairment 18.20 13.04 8 27700 111726 79604954
Jaundice cholestatic 18.17 13.04 21 27687 11263 79705417
Encephalopathy 18.04 13.04 58 27650 67339 79649341
Hypoventilation 18.03 13.04 17 27691 7207 79709473
Arthropathy 17.99 13.04 21 27687 177090 79539590
Spinal cord haematoma 17.95 13.04 6 27702 319 79716361
COVID-19 17.92 13.04 17 27691 157657 79559023
Eye abscess 17.65 13.04 6 27702 336 79716344
Mixed liver injury 17.34 13.04 17 27691 7561 79709119
Resorption bone increased 17.31 13.04 9 27699 1466 79715214
Loss of personal independence in daily activities 17.26 13.04 7 27701 102573 79614107
Implant site haematoma 17.22 13.04 5 27703 166 79716514
Fear of death 17.07 13.04 9 27699 1507 79715173
Factor V inhibition 17.02 13.04 6 27702 375 79716305
Inappropriate schedule of product administration 16.90 13.04 13 27695 133615 79583065
Delayed graft function 16.67 13.04 12 27696 3495 79713185
Acute kidney injury 16.64 13.04 263 27445 519141 79197539
Procedural complication 16.60 13.04 17 27691 7966 79708714
Therapeutic product effect incomplete 16.42 13.04 15 27693 141630 79575050
Staphylococcal infection 16.37 13.04 51 27657 58244 79658436
Mycobacterial peritonitis 16.27 13.04 4 27704 69 79716611
Balance disorder 16.23 13.04 7 27701 98850 79617830
Discomfort 16.17 13.04 12 27696 125605 79591075
Cutaneous vasculitis 16.13 13.04 17 27691 8235 79708445
Feeling abnormal 16.04 13.04 19 27689 159180 79557500
Lip oedema 16.03 13.04 15 27693 6301 79710379
General physical health deterioration 16.01 13.04 46 27662 275192 79441488
Anaphylactoid reaction 15.97 13.04 14 27694 5408 79711272
Sleep disorder 15.86 13.04 5 27703 85672 79631008
Toxic shock syndrome 15.75 13.04 8 27700 1241 79715439
Coagulation factor VII level decreased 15.72 13.04 5 27703 227 79716453
Vestibular disorder 15.47 13.04 10 27698 2445 79714235
Alanine aminotransferase increased 15.40 13.04 103 27605 162467 79554213
Hypothermia 15.33 13.04 28 27680 22718 79693962
Dyspnoea 15.29 13.04 208 27500 856817 78859863
Jaundice 15.28 13.04 47 27661 53302 79663378
Psoriasis 15.26 13.04 6 27702 89581 79627099
Irregular breathing 15.22 13.04 6 27702 512 79716168
Swelling 15.11 13.04 33 27675 216678 79500002
Fungal infection 15.09 13.04 40 27668 41708 79674972
Wound 15.08 13.04 11 27697 116168 79600512
Cardiac valve vegetation 14.93 13.04 7 27701 912 79715768
Myalgia 14.91 13.04 26 27682 185615 79531065
Oxygen saturation decreased 14.88 13.04 86 27622 128961 79587719
Hypersensitivity vasculitis 14.83 13.04 15 27693 6928 79709752
Vertigo 14.77 13.04 3 27705 69079 79647601
Spontaneous haematoma 14.77 13.04 8 27700 1414 79715266
Influenza 14.69 13.04 14 27694 129592 79587088
Arthritis bacterial 14.66 13.04 17 27691 9149 79707531
Cataract subcapsular 14.63 13.04 7 27701 954 79715726
Torsade de pointes 14.60 13.04 25 27683 19287 79697393
Syncope 14.53 13.04 25 27683 179424 79537256
Laryngeal dyspnoea 14.44 13.04 5 27703 296 79716384
Cough 14.39 13.04 72 27636 366717 79349963
Drug chemical incompatibility 14.23 13.04 4 27704 118 79716562
Jaundice acholuric 14.20 13.04 4 27704 119 79716561
Exposure during pregnancy 14.10 13.04 71 27637 101061 79615619
Propionibacterium infection 14.04 13.04 5 27703 322 79716358
Blood creatinine increased 13.95 13.04 97 27611 154960 79561720
Systemic mastocytosis 13.89 13.04 5 27703 332 79716348
Altered state of consciousness 13.87 13.04 40 27668 43782 79672898
Decorticate posture 13.82 13.04 5 27703 337 79716343
Procedural pain 13.80 13.04 27 27681 23057 79693623
Cerebral infarction 13.80 13.04 41 27667 45635 79671045
Eosinophilic pneumonia acute 13.75 13.04 7 27701 1091 79715589
Injection site erythema 13.72 13.04 5 27703 78192 79638488
Respiratory distress 13.66 13.04 48 27660 58291 79658389
International normalised ratio increased 13.64 13.04 62 27646 84659 79632021
Stevens-Johnson syndrome 13.63 13.04 37 27671 39129 79677551
Hypoaesthesia 13.61 13.04 26 27682 179326 79537354
Endotracheal intubation 13.58 13.04 12 27696 4685 79711995
Back pain 13.54 13.04 57 27651 304123 79412557
Hypokalaemia 13.49 13.04 91 27617 143949 79572731
Status epilepticus 13.43 13.04 28 27680 25013 79691667
Fibromyalgia 13.34 13.04 3 27705 64337 79652343
Gait disturbance 13.34 13.04 33 27675 207473 79509207
Blood pressure increased 13.28 13.04 34 27674 211326 79505354
Serotonin syndrome 13.21 13.04 40 27668 44987 79671693
Stupor 13.15 13.04 14 27694 6858 79709822
Eosinophilic myocarditis 13.04 13.04 7 27701 1215 79715465

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DB04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
First-generation cephalosporins
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Bacterial septicemia indication 10001005 DOID:0040085
Infection of skin AND/OR subcutaneous tissue indication 19824006
Staphylococcal pneumonia indication 22754005
Pneumonia due to Streptococcus indication 34020007
Lower respiratory tract infection indication 50417007
Bacterial pneumonia indication 53084003 DOID:874
Cholangitis indication 82403002 DOID:9446
Infection of bone indication 111253001
Bacterial endocarditis indication 301183007
Bacterial urinary infection indication 312124009
Infectious disorder of joint indication 363162000
Infection of biliary tract indication 846685008
Prevention of Perioperative Infection indication
Genitourinary Tract Infections indication
Prevention of Bacterial Endocarditis off-label use
Acute nephropathy contraindication 58574008
Blood coagulation disorder contraindication 64779008 DOID:1247
Factor II deficiency contraindication 73975000
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.22 acidic
pKa2 12.21 acidic
pKa3 1.52 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 1GM BASE/VIAL CEFAZOLIN AND DEXTROSE B BRAUN N050779 July 27, 2000 RX INJECTABLE INJECTION Nov. 23, 2023 NEW PATIENT POPULATION
EQ 2GM BASE/VIAL CEFAZOLIN AND DEXTROSE B BRAUN N050779 Jan. 13, 2012 RX INJECTABLE INJECTION Nov. 23, 2023 NEW PATIENT POPULATION
EQ 500MG BASE/VIAL CEFAZOLIN AND DEXTROSE B BRAUN N050779 July 27, 2000 DISCN INJECTABLE INJECTION Nov. 23, 2023 NEW PATIENT POPULATION

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 1A Enzyme WOMBAT-PK

External reference:

IDSource
4019659 VUID
N0000147751 NUI
D00905 KEGG_DRUG
27164-46-1 SECONDARY_CAS_RN
203171 RXNORM
C0007546 UMLSCUI
CHEBI:474053 CHEBI
CHEMBL1435 ChEMBL_ID
CHEMBL1200523 ChEMBL_ID
D002437 MESH_DESCRIPTOR_UI
DB01327 DRUGBANK_ID
10935 IUPHAR_LIGAND_ID
2991 INN_ID
IHS69L0Y4T UNII
33255 PUBCHEM_CID
35509 MMSL
4371 MMSL
948 MMSL
d00007 MMSL
387470007 SNOMEDCT_US
80972005 SNOMEDCT_US
81088002 SNOMEDCT_US
4017460 VANDF
4019659 VANDF
002720 NDDF
004841 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9139 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS NDA 28 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9140 INJECTION, POWDER, FOR SOLUTION 3 g INTRAVENOUS NDA 28 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9261 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 23 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9262 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9262 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9665 INJECTION, POWDER, FOR SOLUTION 20 g INTRAVENOUS ANDA 23 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9923 INJECTION, POWDER, FOR SOLUTION 225 mg INTRAMUSCULAR ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9923 INJECTION, POWDER, FOR SOLUTION 225 mg INTRAMUSCULAR ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9924 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9924 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9983 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 23 sections
Cefazolin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0264-3103 SOLUTION 1 g INTRAVENOUS NDA 27 sections
Cefazolin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0264-3105 SOLUTION 2 g INTRAVENOUS NDA 27 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0338-3503 INJECTION, SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0338-3503 INJECTION, SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0338-3503 INJECTION, SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0338-3508 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 26 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0338-3508 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 26 sections
CEFAZOLIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9833 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 17 sections
CEFAZOLIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9833 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 17 sections
CEFAZOLIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9833 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 17 sections
CEFAZOLIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9834 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 10 sections
CEFAZOLIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9834 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 10 sections
CEFAZOLIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9834 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 10 sections
CEFAZOLIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9835 INJECTION, POWDER, FOR SOLUTION 225 mg INTRAMUSCULAR ANDA 11 sections
CEFAZOLIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9835 INJECTION, POWDER, FOR SOLUTION 225 mg INTRAMUSCULAR ANDA 11 sections
CEFAZOLIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9835 INJECTION, POWDER, FOR SOLUTION 225 mg INTRAMUSCULAR ANDA 11 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0409-2585 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 23 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0781-3450 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 21 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0781-3451 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 21 sections